KYTHERA Biopharmaceuticals Announces Positive Interim Phase IIIb Results from Open-Label Study of ATX-101
April 06, 2013 at 10:52 AM EDT
KYTHERA Biopharmaceuticals (NASDAQ: KYTH ) today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the “Innovations and Renewals” session of the
